Ardelyx Targets 2027 Profitability as IBSRELA Faces Insurance Hurdles
Ardelyx (ARDX) aims for profitability by 2027, with IBSRELA facing insurance challenges. The company reported a 32% gross-to-net rate, allowing some pricing flexibility. Ardelyx completed enrollment in a Phase 3 trial for IBSRELA in chronic idiopathic constipation, with data expected in 2027. The company expects IBSRELA to reach $1 billion in sales but removed a specific timeframe. Ardelyx had $285 million in cash at the end of September and plans to use future cash flow for pipeline expansion.



